Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Pancreatic Cancer
Interventions
DRUG

Norzyme

Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.

Trial Locations (1)

410-769

NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,, Goyang-si

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pharmbio Korea Co., Ltd.

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV